Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Key Points

• JPMorgan raised Replimune Group’s price target to $21 from $20 and maintained an “overweight” rating, implying 38.29% upside from the reported $15.19 share price.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and average price target of $12.00, though ratings range from Strong Buy to Sell.
• Replimune reported a quarterly loss of $0.72 per share, missing estimates by $0.03. The clinical-stage biotech is developing oncolytic immunotherapies for solid tumors, including its lead candidate RP1.

Replimune Group (NASDAQ:REPL - Get Free Report) had its target price boosted by JPMorgan Chase & Co. from $20.00 to $21.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 38.29% from the stock's current price.

Other equities analysts have also recently issued research reports about the company. Leerink Partners upgraded Replimune Group from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $11.00 to $17.00 in a report on Tuesday, August 4th. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective on the stock in a research note on Friday, August 7th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Replimune Group in a research report on Wednesday, August 12th. BMO Capital Markets upgraded Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 target price for the company in a research note on Tuesday, June 30th. Finally, Weiss Ratings lowered Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Replimune Group currently has a consensus rating of "Moderate Buy" and an average price target of $12.00.

Replimune Group Stock Performance

Shares of REPL stock opened at $15.19 on Wednesday. The stock has a market cap of $1.42 billion, a P/E ratio of -4.85 and a beta of 0.88. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The company has a fifty day moving average price of $11.51 and a two-hundred day moving average price of $8.17. Replimune Group has a one year low of $1.50 and a one year high of $15.89.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, equities analysts predict that Replimune Group will post -2.94 EPS for the current year.

Insider Activity

In other news, insider Konstantinos Xynos sold 11,447 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the transaction, the insider owned 224,215 shares of the company's stock, valued at approximately $2,908,068.55. This represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 91,124 shares of company stock valued at $1,149,244. Company insiders own 5.40% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in REPL. California State Teachers Retirement System increased its position in Replimune Group by 185.3% during the second quarter. California State Teachers Retirement System now owns 11,114 shares of the company's stock worth $123,000 after acquiring an additional 7,218 shares during the period. Readystate Asset Management LP boosted its holdings in Replimune Group by 116.6% in the 2nd quarter. Readystate Asset Management LP now owns 299,958 shares of the company's stock valued at $3,321,000 after purchasing an additional 161,470 shares during the period. Syon Capital LLC bought a new stake in Replimune Group in the 2nd quarter valued at about $247,000. AXQ Capital LP grew its position in shares of Replimune Group by 4.1% during the 2nd quarter. AXQ Capital LP now owns 27,121 shares of the company's stock worth $300,000 after purchasing an additional 1,056 shares in the last quarter. Finally, Montanova Capital LLC grew its position in shares of Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company's stock worth $48,595,000 after purchasing an additional 168,000 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source